The New York Times: Treating PTSD With MDMA? You Might Have Some Questions.

May 1, 2018 | News

Originally appearing here.

Summary: The New York Times reports on the newly published results of MAPS’ U.S. Food and Drug Administration (FDA)-regulated clinical trial of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) in veterans, firefighters, and police officers. The New York Times speaks with MAPS-sponsored MDMA researcher Michael Mithoefer, M.D., and trial participants Nigel McCourry and Nicholas Blackston.

“The MDMA alone or the therapy alone don’t appear to be as effective,” explains Mithoefer. “The MDMA seems to act as a catalyst that allows the healing to happen.”

“I was actually able to forgive myself,” explains McCourry. “There are also still some challenges I have to face from time to time related to the PTSD. But now I am able to work through them without getting stuck.”



MAPS Public Benefit Corporation

Our Mission
Who We Are
Contact Us
Privacy Policy

Cookie Policy

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

Therapy Education for Healthcare Providers

Our Commitment to Therapy Education


MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about the MDMA-AT Education Program

You have Successfully Subscribed!